59.61
-1.48 (-2.42%)
| Penutupan Terdahulu | 61.09 |
| Buka | 61.08 |
| Jumlah Dagangan | 1,464,051 |
| Purata Dagangan (3B) | 1,383,748 |
| Modal Pasaran | 7,584,001,536 |
| Harga / Pendapatan (P/E TTM) | 19.74 |
| Harga / Pendapatan (P/E Ke hadapan) | 10.91 |
| Harga / Jualan (P/S) | 6.52 |
| Harga / Buku (P/B) | 13.36 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 31 Oct 2024 |
| Margin Keuntungan | 41.43% |
| Margin Operasi (TTM) | 56.26% |
| EPS Cair (TTM) | 3.02 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 34.30% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 67.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 339.05% |
| Nisbah Semasa (MRQ) | 10.36 |
| Aliran Tunai Operasi (OCF TTM) | 402.95 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 339.29 M |
| Pulangan Atas Aset (ROA TTM) | 14.87% |
| Pulangan Atas Ekuiti (ROE TTM) | 111.83% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Halozyme Therapeutics, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 4.0 |
| Purata | 1.13 |
|
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.06% |
| % Dimiliki oleh Institusi | 100.80% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 73.00 (JMP Securities, 22.46%) | Beli |
| Median | 63.50 (6.53%) | |
| Rendah | 53.00 (Piper Sandler, -11.09%) | Pegang |
| Purata | 63.25 (6.11%) | |
| Jumlah | 2 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 54.22 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wells Fargo | 13 Jan 2025 | 57.00 (-4.38%) | Pegang | 54.14 |
| HC Wainwright & Co. | 10 Jan 2025 | 70.00 (17.43%) | Beli | 52.80 |
| 30 Dec 2024 | 68.00 (14.07%) | Beli | 47.99 | |
| Piper Sandler | 10 Jan 2025 | 53.00 (-11.09%) | Pegang | 52.80 |
| 04 Nov 2024 | 52.00 (-12.77%) | Pegang | 58.47 | |
| JMP Securities | 01 Nov 2024 | 73.00 (22.46%) | Beli | 57.15 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |